羚邦(02230.HK)料今年動漫展銷售錄雙位數增長
羚邦(02230.HK)主席兼行政總裁趙小燕表示,預計本月底的動漫展會較往年設置更多攤位及商品,相信銷售會錄得雙位數升幅,有助抵銷成本上升。
她稱,集團目前的媒體內容版權已超過650個,按年上升9.3%,單計今年首季已經購入約20個媒體內容版權,當中以日漫為主,集團將在今年餘下時間繼續進行併購,相信短期內會有一宗IP管理相關業務的併購。
她又提到,會繼續擴闊媒體串流業務的覆蓋率,以及為旗下串流平台Ani-One在多個市場進行本地化,集團今年已完成收購煜曦電子商務的49%股權,未來將擴闊其銷售網絡至大中華及東南亞地區。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.